Ventilator Associated Bacterial Pneumonia (VABP)

Infectious Diseases
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

BioVersys
BioVersysSwitzerland - Basel
1 program
1
BV100 with 50 mg polymyxin B plus ceftazidime/avibactamPhase 21 trial
Active Trials
NCT07431307Not Yet Recruiting120Est. Jul 2028

Trial Timeline

Clinical trial activity over time

2026
2027
2028
BioVersysBV100 with 50 mg polymyxin B plus ceftazidime/avibactam

Clinical Trials (1)

Total enrollment: 120 patients across 1 trials

NCT07431307BioVersysBV100 with 50 mg polymyxin B plus ceftazidime/avibactam

Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

Start: Jul 2026Est. completion: Jul 2028120 patients
Phase 2Not Yet Recruiting

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space